# Procore Technologies, Inc.: financial statements, quarterly

PCOR · NYSE · CIK 1611052 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pcor.md) · [Financials](/companies/pcor/financials.md) · [Filings](/companies/pcor/filings.md) · [Insiders](/companies/pcor/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pcor/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [248](/filings/0001628280-24-044546.md) | [260 d](/filings/0001628280-26-011055.md) | [269](/filings/0001628280-25-021898.md) | [284](/filings/0001611052-25-000007.md) | [296](/filings/0001628280-25-050149.md) | [302 d](/filings/0001628280-26-011055.md) | [311](/filings/0001628280-26-031230.md) | [324](/filings/0001628280-26-051460.md) | [339](/filings/0001628280-25-050149.md) | [349 d](/filings/0001628280-26-011055.md) | [359](/filings/0001628280-26-031230.md) | [375](/filings/0001628280-26-051460.md) |
| Cost of revenue | $m | [44.1](/filings/0001628280-24-044546.md) | [47.8 d](/filings/0001628280-26-011055.md) | [45.7](/filings/0001628280-25-021898.md) | [48.1](/filings/0001611052-25-000007.md) | [55.0](/filings/0001628280-25-050149.md) | [56.8 d](/filings/0001628280-26-011055.md) | [64.9](/filings/0001628280-26-031230.md) | [67.7](/filings/0001628280-26-051460.md) | [68.8](/filings/0001628280-25-050149.md) | [69.4 d](/filings/0001628280-26-011055.md) | [71.5](/filings/0001628280-26-031230.md) | [75.4](/filings/0001628280-26-051460.md) |
| Gross profit | $m | [204](/filings/0001628280-24-044546.md) | [212 d](/filings/0001628280-26-011055.md) | [224](/filings/0001628280-25-021898.md) | [236](/filings/0001611052-25-000007.md) | [241](/filings/0001628280-25-050149.md) | [245 d](/filings/0001628280-26-011055.md) | [246](/filings/0001628280-26-031230.md) | [256](/filings/0001628280-26-051460.md) | [270](/filings/0001628280-25-050149.md) | [280 d](/filings/0001628280-26-011055.md) | [288](/filings/0001628280-26-031230.md) | [300](/filings/0001628280-26-051460.md) |
| Research and development | $m | [72.7](/filings/0001628280-24-044546.md) | [74.6 d](/filings/0001628280-26-011055.md) | [70.6](/filings/0001628280-25-021898.md) | [72.3](/filings/0001611052-25-000007.md) | [80.8](/filings/0001628280-25-050149.md) | [89.3 d](/filings/0001628280-26-011055.md) | [87.6](/filings/0001628280-26-031230.md) | [88.9](/filings/0001628280-26-051460.md) | [88.0](/filings/0001628280-25-050149.md) | [97.8 d](/filings/0001628280-26-011055.md) | [85.6](/filings/0001628280-26-031230.md) | [93.3](/filings/0001628280-26-051460.md) |
| Operating income | $m | [(50.4)](/filings/0001628280-24-044546.md) | [(37.3) d](/filings/0001628280-26-011055.md) | [(18.9)](/filings/0001628280-25-021898.md) | [(14.8)](/filings/0001611052-25-000007.md) | [(36.5)](/filings/0001628280-25-050149.md) | [(66.2) d](/filings/0001628280-26-011055.md) | [(36.2)](/filings/0001628280-26-031230.md) | [(30.3)](/filings/0001628280-26-051460.md) | [(15.0)](/filings/0001628280-25-050149.md) | [(42.8) d](/filings/0001628280-26-011055.md) | [(15.7)](/filings/0001628280-26-031230.md) | [4.3](/filings/0001628280-26-051460.md) |
| Interest expense | $m | [0.5](/filings/0001611052-23-000014.md) | [0.5 d](/filings/0001628280-24-006848.md) | [0.5](/filings/0001628280-24-019989.md) | [0.5](/filings/0001611052-25-000007.md) | [0.5](/filings/0001628280-25-050149.md) | [0.5 d](/filings/0001628280-26-011055.md) | [0.3](/filings/0001628280-26-031230.md) | [0.3](/filings/0001628280-26-051460.md) | [0.3](/filings/0001628280-25-050149.md) | [0.3 d](/filings/0001628280-26-011055.md) | [0.3](/filings/0001628280-26-031230.md) | [0.2](/filings/0001628280-26-051460.md) |
| Income tax | $m | [0.2](/filings/0001628280-24-044546.md) | [0.7 d](/filings/0001628280-26-011055.md) | [0.3](/filings/0001628280-25-021898.md) | [0.5](/filings/0001611052-25-000007.md) | [(0.4)](/filings/0001628280-25-050149.md) | [1.4 d](/filings/0001628280-26-011055.md) | [5.3](/filings/0001628280-26-031230.md) | [(0.4)](/filings/0001628280-26-051460.md) | [0.5](/filings/0001628280-25-050149.md) | [1.4 d](/filings/0001628280-26-011055.md) | [(1.9)](/filings/0001628280-26-031230.md) | [(1.8)](/filings/0001628280-26-051460.md) |
| Net income | $m | [(43.8)](/filings/0001628280-24-044546.md) | [(29.5) d](/filings/0001628280-26-011055.md) | [(11.0)](/filings/0001628280-25-021898.md) | [(6.3)](/filings/0001611052-25-000007.md) | [(26.4)](/filings/0001628280-25-050149.md) | [(62.3) d](/filings/0001628280-26-011055.md) | [(33.0)](/filings/0001628280-26-031230.md) | [(21.1)](/filings/0001628280-26-051460.md) | [(9.1)](/filings/0001628280-25-050149.md) | [(37.6) d](/filings/0001628280-26-011055.md) | [(9.1)](/filings/0001628280-26-031230.md) | [16.9](/filings/0001628280-26-051460.md) |
| Diluted EPS | $ per share | [(0.31)](/filings/0001628280-24-044546.md) | not reported | [(0.08)](/filings/0001628280-25-021898.md) | [(0.04)](/filings/0001611052-25-000007.md) | [(0.18)](/filings/0001628280-25-050149.md) | not reported | [(0.22)](/filings/0001628280-26-031230.md) | [(0.14)](/filings/0001628280-26-051460.md) | [(0.06)](/filings/0001628280-25-050149.md) | not reported | [(0.06)](/filings/0001628280-26-031230.md) | [0.11](/filings/0001628280-26-051460.md) |
| Basic EPS | $ per share | [(0.31)](/filings/0001628280-24-044546.md) | not reported | [(0.08)](/filings/0001628280-25-021898.md) | [(0.04)](/filings/0001611052-25-000007.md) | [(0.18)](/filings/0001628280-25-050149.md) | not reported | [(0.22)](/filings/0001628280-26-031230.md) | [(0.14)](/filings/0001628280-26-051460.md) | [(0.06)](/filings/0001628280-25-050149.md) | not reported | [(0.06)](/filings/0001628280-26-031230.md) | [0.11](/filings/0001628280-26-051460.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [318](/filings/0001611052-23-000014.md) | [358](/filings/0001628280-26-011055.md) | [428](/filings/0001628280-24-019989.md) | [356](/filings/0001628280-24-034402.md) | [439](/filings/0001628280-25-050149.md) | [438](/filings/0001628280-26-011055.md) | [314](/filings/0001628280-26-031230.md) | [324](/filings/0001628280-26-051460.md) | [350](/filings/0001628280-25-050149.md) | [481](/filings/0001628280-26-051460.md) | [386](/filings/0001628280-26-031230.md) | [494](/filings/0001628280-26-051460.md) |
| Current assets | $m | [842](/filings/0001611052-23-000014.md) | [956](/filings/0001628280-25-008121.md) | [955](/filings/0001628280-24-019989.md) | [966](/filings/0001628280-24-034402.md) | [1,017](/filings/0001628280-24-044546.md) | [1,100](/filings/0001628280-26-011055.md) | [816](/filings/0001628280-25-021898.md) | [913](/filings/0001611052-25-000007.md) | [1,005](/filings/0001628280-25-050149.md) | [1,167](/filings/0001628280-26-051460.md) | [901](/filings/0001628280-26-031230.md) | [1,043](/filings/0001628280-26-051460.md) |
| Total assets | $m | [1,783](/filings/0001611052-23-000014.md) | [1,894](/filings/0001628280-25-008121.md) | [1,879](/filings/0001628280-24-019989.md) | [1,967](/filings/0001628280-24-034402.md) | [2,019](/filings/0001628280-24-044546.md) | [2,101](/filings/0001628280-26-011055.md) | [1,949](/filings/0001628280-25-021898.md) | [2,004](/filings/0001611052-25-000007.md) | [2,058](/filings/0001628280-25-050149.md) | [2,239](/filings/0001628280-26-051460.md) | [2,108](/filings/0001628280-26-031230.md) | [2,244](/filings/0001628280-26-051460.md) |
| Current liabilities | $m | [562](/filings/0001611052-23-000014.md) | [642](/filings/0001628280-25-008121.md) | [595](/filings/0001628280-24-019989.md) | [625](/filings/0001628280-24-034402.md) | [649](/filings/0001628280-24-044546.md) | [728](/filings/0001628280-26-011055.md) | [686](/filings/0001628280-25-021898.md) | [706](/filings/0001611052-25-000007.md) | [754](/filings/0001628280-25-050149.md) | [885](/filings/0001628280-26-051460.md) | [807](/filings/0001628280-26-031230.md) | [891](/filings/0001628280-26-051460.md) |
| Total liabilities | $m | [659](/filings/0001611052-23-000014.md) | [738](/filings/0001628280-25-008121.md) | [685](/filings/0001628280-24-019989.md) | [711](/filings/0001628280-24-034402.md) | [733](/filings/0001628280-24-044546.md) | [813](/filings/0001628280-26-011055.md) | [767](/filings/0001628280-25-021898.md) | [787](/filings/0001611052-25-000007.md) | [834](/filings/0001628280-25-050149.md) | [977](/filings/0001628280-26-051460.md) | [908](/filings/0001628280-26-031230.md) | [965](/filings/0001628280-26-051460.md) |
| Shareholders' equity | $m | [1,124](/filings/0001628280-24-044546.md) | [1,156](/filings/0001628280-26-011055.md) | [1,194](/filings/0001628280-25-050149.md) | [1,256](/filings/0001628280-25-050149.md) | [1,286](/filings/0001628280-25-050149.md) | [1,288](/filings/0001628280-26-051460.md) | [1,182](/filings/0001628280-26-051460.md) | [1,218](/filings/0001628280-26-051460.md) | [1,224](/filings/0001628280-25-050149.md) | [1,262](/filings/0001628280-26-051460.md) | [1,200](/filings/0001628280-26-051460.md) | [1,278](/filings/0001628280-26-051460.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [33.7 d](/filings/0001628280-24-044546.md) | [40.7 d](/filings/0001628280-26-011055.md) | [69.1](/filings/0001628280-25-021898.md) | [58.7 d](/filings/0001611052-25-000007.md) | [39.3 d](/filings/0001628280-25-050149.md) | [29.1 d](/filings/0001628280-26-011055.md) | [66.0](/filings/0001628280-26-031230.md) | [30.8 d](/filings/0001628280-26-051460.md) | [88.5 d](/filings/0001628280-25-050149.md) | [115 d](/filings/0001628280-26-011055.md) | [76.8](/filings/0001628280-26-031230.md) | [87.9 d](/filings/0001628280-26-051460.md) |
| Capital expenditure | $m | [3.4 d](/filings/0001628280-24-044546.md) | [2.3 d](/filings/0001628280-26-011055.md) | [2.1](/filings/0001628280-25-021898.md) | [1.9 d](/filings/0001611052-25-000007.md) | [3.5 d](/filings/0001628280-25-050149.md) | [11.6 d](/filings/0001628280-26-011055.md) | [4.0](/filings/0001628280-26-031230.md) | [3.0 d](/filings/0001628280-26-051460.md) | [5.4 d](/filings/0001628280-25-050149.md) | [5.7 d](/filings/0001628280-26-011055.md) | [2.9](/filings/0001628280-26-031230.md) | [7.0 d](/filings/0001628280-26-051460.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001628280-25-021898.md) | [0.0 d](/filings/0001611052-25-000007.md) | [0.0 d](/filings/0001628280-25-050149.md) | [0.0 d](/filings/0001628280-26-011055.md) | [100](/filings/0001628280-26-031230.md) | [3.1 d](/filings/0001628280-26-051460.md) | [25.7 d](/filings/0001628280-25-050149.md) | [0.0 d](/filings/0001628280-26-011055.md) | [100](/filings/0001628280-26-031230.md) | [0.0 d](/filings/0001628280-26-051460.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [137](/filings/0001611052-23-000014.md) | [140](/filings/0001628280-24-019989.md) | [141](/filings/0001628280-24-034402.md) | [143](/filings/0001628280-24-044546.md) | [145](/filings/0001628280-25-021898.md) | [147](/filings/0001611052-25-000007.md) | [148](/filings/0001628280-25-050149.md) | [150](/filings/0001628280-26-031230.md) | [150](/filings/0001628280-26-051460.md) | [150](/filings/0001628280-25-050149.md) | [151](/filings/0001628280-26-031230.md) | [153](/filings/0001628280-26-051460.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 151,955,338 at 2026-07-24, from the cover of the [10-Q filed 2026-07-31](/filings/0001628280-26-051460.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.